银屑病关节炎患者骨质疏松患病率及骨密度检测相关因素
该研究纳入多伦多银屑病关节炎(PsA)队列中至2019年1月有骨密度(BMD)检测结果的214例患者,描述腰椎、股骨颈和全髋T评分,并分析BMD检测的预测因素及PsA临床活动对BMD的影响。结果显示骨量减少和骨质疏松分别占45.27%和12.94%,年龄增加、绝经、急性期反应物升高及使用生物制剂、甲氨蝶呤和全身糖皮质激素与接受BMD检测几率较高相关。
要点
- PsA队列中骨量减少占45.27%,骨质疏松占12.94%。
- 年龄增加、绝经、急性期反应物升高及使用生物制剂、甲氨蝶呤、全身糖皮质激素与BMD检测几率较高相关。
- BMI增加和生物制剂使用与骨质疏松范围BMD结果几率较低相关。
核心结论
- PsA队列中骨量减少和骨质疏松的患病率与一般人群相似。
- 临床医生正利用骨质疏松危险因素和PsA疾病严重程度标志物来选择患者进行BMD检测。
- 多关节炎可能预示随时间推移BMD结果更差,但因患者数量少未达统计学显著性。
- 生物制剂使用和BMI增加似乎具有保护作用。
研究设计与样本
- 研究纳入多伦多大学PsA诊所从队列起始至2019年1月有BMD检测结果的患者,共1479例中214例接受BMD检测。
- 采用描述性统计总结腰椎、股骨颈和全髋T评分。
- 采用Cox比例风险回归识别BMD检测的预测因素。
- 采用逻辑回归分析确定正常BMD(T评分≥-1.0)与骨质疏松范围BMD(T评分≤-2.5)的比值比。
- 采用多状态模型确定与BMD状态随时间变化相关的因素。
主要发现
- 腰椎、股骨颈和全髋的平均±SD T评分分别为-0.30±0.32、-1.10±1.04和-0.45±0.42。
- 骨量减少和骨质疏松分别发生于45.27%和12.94%的患者。
- 年龄增加、绝经、急性期反应物升高以及使用生物制剂、甲氨蝶呤和全身糖皮质激素与接受BMD检测的较高几率相关。
- BMI增加和生物制剂使用与骨质疏松范围BMD检测结果的较低几率相关。
- 在多状态分析中,多关节炎可能预示随时间推移BMD结果更低,但因患者数量少未达统计学显著性。
临床怎么用
- 临床医生可利用骨质疏松危险因素(如年龄增加、绝经、急性期反应物升高)和PsA疾病严重程度标志物(如多关节炎)来选择患者进行BMD检测。
- 生物制剂使用和BMI增加与较低的骨质疏松范围BMD结果几率相关,可能具有保护作用。
局限性
- 多状态分析中多关节炎与BMD结果随时间变化的关系因患者数量少未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine bone mineral density (BMD) in psoriatic arthritis (PsA) patients, factors associated with undergoing BMD testing, and the effect of PsA clinical activity on BMD. METHODS: Patients attending the University of Toronto PsA Clinic with BMD testing results from cohort inception to January 2019 were included. Descriptive statistics summarized lumbar spine, femoral neck, and total hip T scores. Cox proportional hazards regression identified predictors for BMD testing. Logistic regression analysis determined odds of having normal (T score -1.0 or more) versus osteoporotic-range BMD (T score -2.5 or less). A multistate model determined factors associated with BMD state changes over time. RESULTS: Of the 1,479 patients, 214 had BMD tests performed. The mean ± SD T scores at the lumbar spine, femoral neck, and total hip were -0.30 ± 0.32, -1.10 ± 1.04, and -0.45 ± 0.42, respectively. Osteopenia and osteoporosis occurred in 45.27% and 12.94% of patients. Increasing age, menopause, elevated acute-phase reactants, and biologics, methotrexate, and systemic glucocorticoids use were associated with a higher chance of undergoing BMD testing. Increased body mass index (BMI) and biologics use were associated with a lower chance of having osteoporotic-range BMD test results. In multistate analysis, polyarthritis may portend lower BMD results over time, although this did not achieve statistical significance due to low patient numbers. CONCLUSION: The prevalence of osteopenia and osteoporosis in the PsA cohort was similar to that of the general population. Clinicians are using osteoporosis risk factors and PsA disease severity markers to select patients for BMD testing. Polyarticular disease may portend worse BMD test results. Biologic use and increased BMI appear to have a protective effect.
引用
- Kwok TSH, Sutton M, Ye JY, et al. Prevalence and Factors Associated With Osteoporosis and Bone Mineral Density Testing in Psoriatic Arthritis. Arthritis Care Res (Hoboken). 2022. PMID: 33326187. doi:10.1002/acr.24538
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。